Associate Director, Biostatistics
TLDR
Own trial analyses and presented data for the Deramiocel program, authoring SAPs and informing clinical, regulatory, and corporate decisions.
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel (CAP-1002), our lead cell therapy in late-stage development for Duchenne muscular dystrophy. We are also harnessing our proprietary StealthX™ exosome platform to unlock new possibilities in targeted delivery and vaccinology. Every program reflects our commitment to pushing the boundaries of science and delivering life-changing treatments to patients and families who need them most.
As the Associate Director, Biostatistics at Capricor, you will join a lean, high-impact team that owns all analysis and presented data across the company. Reporting to the Head of Biostatistics, you will be a hands-on biostatistician supporting the Deramiocel program in cardiomyopathy associated with Duchenne muscular dystrophy (DMD), authoring SAPs and delivering the analyses behind clinical and corporate decisions. The team plans and executes every trial analysis and is forward-facing to regulatory agencies, the patient community, and the investment community. The ideal candidate brings deep SAP authoring experience, sound statistical judgment, and the ability to communicate results clearly to technical and non-technical audiences.
Responsibilities
Required Qualifications
Preferred Qualifications
Why Capricor?
Capricor Therapeutics is advancing cell and exosome-based therapies with a focus on serious diseases where patients and families need new treatment options. Our work is grounded in scientific rigor, collaboration, and a shared commitment to moving meaningful therapies forward. Joining Capricor means being part of a mission-driven team working at the intersection of innovation, execution, and patient impact.
Come Work With Us
At Capricor, you’ll join a collaborative environment where employees are encouraged to contribute, grow, and help build the systems, science, and operations needed to support our next stage of growth. We value people who are thoughtful, accountable, hands-on, and motivated by work that can make a real difference.
Recruiting Fraud Notice
Capricor does not use Skype for interviews or recruiting activities. Candidates will only be contacted by someone using an official Capricor email address ending in @capricor.com. Capricor will never ask candidates to send money, deposit a check, purchase equipment, or provide payment for any reason as part of the recruiting or onboarding process.
Notice to Recruiting Agencies
Capricor Therapeutics does not accept candidate submissions or referrals from recruiting agencies, staffing firms, or third-party recruiters without express written approval from Talent Acquisition and a fully executed agreement with Capricor. Agencies that contact hiring managers directly, solicit business, or submit candidates without prior approval will not be considered for engagement. Any unsolicited submissions will become the property of Capricor Therapeutics, and no fees will be paid for candidates hired as a result of such submissions. We appreciate your cooperation and respect for this policy.
Benefits
Equity Compensation
long-term equity incentive awards
Health Insurance
company-paid basic life and AD&D insurance
401(k) with company match
a 401(k) plan with company match
Paid Parental Leave
Paid Time Off
paid time off and company holidays
Wellness Stipend
Additional voluntary benefits and wellness programs may also be available.
Capricor Therapeutics is a biotechnology company developing transformative cell and exosome-based therapies aimed at addressing rare diseases. Their lead product, Deramiocel (CAP-1002), is in late-stage development for Duchenne muscular dystrophy, while their proprietary StealthX™ exosome platform explores innovative solutions in targeted delivery and vaccinology.
- Founded
- Founded 2005
- Employees
- 201-500 employees
- Industry
- biotechnology
- Funding stage
- Public
- Stock ticker
- Publicly traded (CAPR)
- Total raised
- $330M raised
- Last funding
- Raised December 2025